Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Double Blind, Randomized, Placebo-controlled, Parallel Group Phase IIa Study of MLR-1023 in Adult Subjects With Uncontrolled Type 2 Diabetes

Next Previous
Trial Profile

A Multi-center, Double Blind, Randomized, Placebo-controlled, Parallel Group Phase IIa Study of MLR-1023 in Adult Subjects With Uncontrolled Type 2 Diabetes

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolimidone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors Melior Pharmaceuticals, Inc.

Most Recent Events

  • 13 Jun 2016 According to a a Melior Discovery media release, results from this study were presented at the 76th Sessions of the American Diabetes Association.
  • 13 Jun 2016 Results published in a Melior Discovery media release.
  • 13 Jun 2016 Primary endpoint has been met. (Change in PPG AUC0-3h in a MMTT between Days 1 and 29.), as reported in a Melior Discovery media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top